NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Journal: Journal Of The National Comprehensive Cancer Network : JNCCN
Published:
Abstract
Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.
Authors
Andrew Zelenetz, Leo Gordon, Jeremy Abramson, Ranjana Advani, Nancy Bartlett, Paolo Caimi, Julie Chang, Julio Chavez, Beth Christian, Luis Fayad, Martha Glenn, Thomas Habermann, Nancy Lee Harris, Francisco Hernandez Ilizaliturri, Mark Kaminski, Christopher Kelsey, Nadia Khan, Susan Krivacic, Ann Lacasce, Amitkumar Mehta, Auayporn Nademanee, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Stephen Smith, Erin Snyder, Lode Swinnen, Julie Vose, Mary Dwyer, Hema Sundar
Relevant Conditions